Newswire (Published: Monday, June 15, 2020, Received: Monday, June 15, 2020, 5:42:43 PM CDT)
Word Count: 532
2020 JUN 15 (NewsRx) -- By a News Reporter-Staff News Editor at NewsRx Drug Daily -- Investigators publish new report on Oncology - Prostate Cancer. According to news originating from St. Gallen, Switzerland, by NewsRx correspondents, research stated, “To evaluate the long-term oncological, functional and toxicity outcomes of low-dose-rate brachytherapy (LDR-BT) in relation to risk factors and radiation dose in a prospective multicentre cohort. Data of patients from 12 Swiss centres undergoing LDR-BT from September 2004 to March 2018 were prospectively collected.”
Our news journalists obtained a quote from the research from the Department of Radiation Oncology, “Patients with a follow-up of 3 months were analysed. Functional and oncological outcomes were assessed at ~6 weeks, 6 and 12 months after implantation and annually thereafter. LDR-BT was performed with I seeds. Dosimetry was done 6 weeks after implantation based on the European Society for Radiotherapy and Oncology recommendations. The Kaplan-Meier method was used for biochemical recurrence-free survival (BRFS). A prostate-specific antigen (PSA) rise above the PSA nadir + 2 was defined as biochemical failure. Functional outcomes were assessed by urodynamic measurement parameters and questionnaires. Of 1580 patients in the database, 1291 (81.7%) were evaluable for therapy outcome. The median (range) follow-up was 37.1 (3.0-141.6) months. Better BRFS was found for Gleason score 3+4 (p=0.03, log-rank test) and initial PSA level of <10 ng/mL (p <0.001). D’Amico Risk groups were significantly associated with BRFS (p <0.001), with a hazard ratio of 2.38 for intermediate-and high-risk patients vs low-risk patients. The radiation dose covering 90% of the prostate volume (D90) after 6 weeks was significantly lower in patients with recurrence. Functional outcomes returned close to baseline levels after 2-3 years. A major limitation of these findings is a substantial loss to follow-up.”
According to the news editors, the research concluded: “Our results are in line with other studies showing that LDR-BT is associated with good oncological outcomes together with good functional results.”
For more information on this research see: Long-term oncological and functional follow-up in low-dose-rate brachytherapy for prostate cancer: results from the prospective nationwide Swiss registry. Bju International, 2020;125(6):827-835. Bju International can be contacted at: Blackwell Publishing Inc, 350 Main St, Malden, MA 02148, USA. (Wiley-Blackwell - http://www.wiley.com/; Bju International - http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1464-410X)
The news correspondents report that additional information may be obtained from P.M. Putora, Dept. of Radiation Oncology, St. Gallen Cantonal Hospital, St. Gallen, Switzerland. Additional authors for this research include P. Viktorin-Baier, H.P. Schmid, L. Plasswilm, C. Schwab, A. Thoeni, W. Hochreiter, L. Prikler, S. Suter, P. Stucki, M. Muntener, N. Blick, H. Schiefer, S. Gusewell, K. Zurn and D. Engeler.
The direct object identifier (DOI) for that additional information is: https://doi.org/10.1111/bju.15003. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.
The publisher’s contact information for the journal Bju International is: Blackwell Publishing Inc, 350 Main St, Malden, MA 02148, USA.
(Our reports deliver fact-based news of research and discoveries from around the world.)
Science and Technology
Health and Wellness
Medical Conditions and Diseases
Men's Health Issues
Medical Specialties and Practices
Treatments and Therapies